nach oben

European Journal of Nuclear Medicine and Molecular Imaging

Erschienen in:

20.02.2016 | Original Article

Development of a nomogram combining clinical staging with ¹⁸F-FDG PET/CT image features in non-small-cell lung cancer stage I–III

verfasst von: Marie-Charlotte Desseroit, Dimitris Visvikis, Florent Tixier, Mohamed Majdoub, Rémy Perdrisot, Rémy Guillevin, Catherine Cheze Le Rest, Mathieu Hatt

Erschienen in: European Journal of Nuclear Medicine and Molecular Imaging | Ausgabe 8/2016

Einloggen, um Zugang zu erhalten

Abstract

Purpose

Our goal was to develop a nomogram by exploiting intratumour heterogeneity on CT and PET images from routine ¹⁸F-FDG PET/CT acquisitions to identify patients with the poorest prognosis.

Methods

This retrospective study included 116 patients with NSCLC stage I, II or III and with staging ¹⁸F-FDG PET/CT imaging. Primary tumour volumes were delineated using the FLAB algorithm and 3D Slicer™ on PET and CT images, respectively. PET and CT heterogeneities were quantified using texture analysis. The reproducibility of the CT features was assessed on a separate test–retest dataset. The stratification power of the PET/CT features was evaluated using the Kaplan-Meier method and the log-rank test. The best standard metric (functional volume) was combined with the least redundant and most prognostic PET/CT heterogeneity features to build the nomogram.

Results

PET entropy and CT zone percentage had the highest complementary values with clinical stage and functional volume. The nomogram improved stratification amongst patients with stage II and III disease, allowing identification of patients with the poorest prognosis (clinical stage III, large tumour volume, high PET heterogeneity and low CT heterogeneity).

Conclusion

Intratumour heterogeneity quantified using textural features on both CT and PET images from routine staging ¹⁸F-FDG PET/CT acquisitions can be used to create a nomogram with higher stratification power than staging alone.

Nur mit Berechtigung zugänglich

Jemal A, Bray F, Center MM, Ferlay J, Ward E, Forman D. Global cancer statistics. CA Cancer J Clin. 2011;61:69–90.CrossRefPubMed

Sauter AW, Schwenzer N, Divine MR, Pichler BJ, Pfannenberg C. Image-derived biomarkers and multimodal imaging strategies for lung cancer management. Eur J Nucl Med Mol Imaging. 2015;42:634–43.CrossRefPubMed

Cook GJ, Yip C, Siddique M, Goh V, Chicklore S, Roy A, et al. Are pretreatment 18F-FDG PET tumor textural features in non-small cell lung cancer associated with response and survival after chemoradiotherapy? J Nucl Med. 2013;54:19–26.CrossRefPubMed

Tixier F, Hatt M, Valla C, Fleury V, Lamour C, Ezzouhri S, et al. Visual versus quantitative assessment of intratumor 18F-FDG PET uptake heterogeneity: prognostic value in non-small cell lung cancer. J Nucl Med. 2014;55:1235–41.CrossRefPubMed

Hatt M, Majdoub M, Vallières M, Tixier F, Le Rest CC, Groheux D, et al. 18F-FDG PET uptake characterization through texture analysis: investigating the complementary nature of heterogeneity and functional tumor volume in a multi-cancer site patient cohort. J Nucl Med. 2015;56:38–44.CrossRefPubMed

Cook GJ, O’Brien ME, Siddique M, Chicklore S, Loi HY, Sharma B, et al. Non-small cell lung cancer treated with erlotinib: heterogeneity of (18)F-FDG uptake at PET – association with treatment response and prognosis. Radiology. 2015;276:883–93.CrossRefPubMed

Pyka T, Bundschuh RA, Andratschke N, Mayer B, Specht HM, Papp L, et al. Textural features in pre-treatment [F18]-FDG-PET/CT are correlated with risk of local recurrence and disease-specific survival in early stage NSCLC patients receiving primary stereotactic radiation therapy. Radiat Oncol. 2015;10:100.CrossRefPubMedPubMedCentral

Win T, Miles KA, Janes SM, Ganeshan B, Shastry M, Endozo R, et al. Tumor heterogeneity and permeability as measured on the CT component of PET/CT predict survival in patients with non-small cell lung cancer. Clin Cancer Res. 2013;19:3591–9.CrossRefPubMed

Aerts HJ, Velazquez ER, Leijenaar RT, Parmar C, Grossmann P, Carvalho S, et al. Decoding tumour phenotype by noninvasive imaging using a quantitative radiomics approach. Nat Commun. 2014;5:4006.PubMedPubMedCentral

10.

Ganeshan B, Goh V, Mandeville HC, Ng QS, Hoskin PJ, Miles KA. Non-small cell lung cancer: histopathologic correlates for texture parameters at CT. Radiology. 2013;266:326–36.CrossRefPubMed

11.

Fried DV, Tucker SL, Zhou S, Liao Z, Mawlawi O, Ibbott G, et al. Prognostic value and reproducibility of pretreatment CT texture features in stage III non-small cell lung cancer. Int J Radiat Oncol Biol Phys. 2014;90:834–42.CrossRefPubMedPubMedCentral

12.

O’Connor JP, Rose CJ, Waterton JC, Carano RA, Parker GJ, Imaging JA, et al. Role in therapy response, resistance, and clinical outcome. Clin Cancer Res. 2015;21:249–57.CrossRefPubMed

13.

Ganeshan B, Miles KA. Quantifying tumour heterogeneity with CT. Cancer Imaging. 2013;13:140–9.CrossRefPubMedPubMedCentral

14.

Vaidya M, Creach KM, Frye J, Dehdashti F, Bradley JD, El Naqa I. Combined PET/CT image characteristics for radiotherapy tumor response in lung cancer. Radiother Oncol. 2012;102:239–45.CrossRefPubMed

15.

Grove O, Berglund AE, Schabath MB, Aerts HJWL, Dekker A, Wang H, et al. Quantitative computed tomographic descriptors associate tumor shape complexity and intratumor heterogeneity with prognosis in lung adenocarcinoma. PLoS One. 2015;10:e0118261.CrossRefPubMedPubMedCentral

16.

Hatt M, Cheze le Rest C, Turzo A, Roux C, Visvikis D. A fuzzy locally adaptive Bayesian segmentation approach for volume determination in PET. IEEE Trans Med Imaging. 2009;28:881–93.CrossRefPubMedPubMedCentral

17.

Hatt M, Cheze le Rest C, Descourt P, Dekker A, De Ruysscher D, Oellers M, et al. Accurate automatic delineation of heterogeneous functional volumes in positron emission tomography for oncology applications. Int J Radiat Oncol Biol Phys. 2010;77:301–8.CrossRefPubMed

18.

Hatt M, Cheze Le Rest C, Albarghach N, Pradier O, Visvikis D. PET functional volume delineation: a robustness and repeatability study. Eur J Nucl Med Mol Imaging. 2011;38:663–72.CrossRefPubMed

19.

Arens AI, Troost EG, Hoeben BA, Grootjans W, Lee JA, Grégoire V, et al. Semiautomatic methods for segmentation of the proliferative tumour volume on sequential FLT PET/CT images in head and neck carcinomas and their relation to clinical outcome. Eur J Nucl Med Mol Imaging. 2014;41:915–24.CrossRefPubMed

20.

Heijmen L, de Geus-Oei LF, de Wilt JH, Visvikis D, Hatt M, Visser EP, et al. Reproducibility of functional volume and activity concentration in 18F-FDG PET/CT of liver metastases in colorectal cancer. Eur J Nucl Med Mol Imaging. 2012;39:1858–67.CrossRefPubMed

21.

Parmar C, Rios Velazquez E, Leijenaar R, Jermoumi M, Carvalho S, Mak RH, et al. Robust radiomics feature quantification using semiautomatic volumetric segmentation. PLoS One. 2014;9:e102107.CrossRefPubMedPubMedCentral

22.

Tixier F, Hatt M, Le Rest CC, Le Pogam A, Corcos L, Visvikis D. Reproducibility of tumor uptake heterogeneity characterization through textural feature analysis in 18F-FDG PET. J Nucl Med. 2012;53:693–700.CrossRefPubMedPubMedCentral

23.

Hunter LA, Krafft S, Stingo F, Choi H, Martel MK, Kry SF, et al. High quality machine-robust image features: identification in nonsmall cell lung cancer computed tomography images. Med Phys. 2013;40:121916.CrossRefPubMedPubMedCentral

24.

Hatt M, Tixier F, Cheze Le Rest C, Pradier O, Visvikis D. Robustness of intratumour 18F-FDG PET uptake heterogeneity quantification for therapy response prediction in oesophageal carcinoma. Eur J Nucl Med Mol Imaging. 2013;40:1662–71.CrossRefPubMed

25.

Armato 3rd SG, Meyer CR, Mcnitt-Gray MF, McLennan G, Reeves AP, Croft BY, et al. The Reference Image Database to Evaluate Response to therapy in lung cancer (RIDER) project: a resource for the development of change-analysis software. Clin Pharmacol Ther. 2008;84:448–56.CrossRefPubMed

26.

Dancey CP, Reidy J. Statistics without maths for psychology. 5th ed. Harlow: Prentice Hall; 2011.

27.

Youden WJ. Index for rating diagnostic tests. Cancer. 1950;3:32–5.CrossRefPubMed

28.

Benjamini Y, Hochberg Y. Controlling the false discovery rate: a practical and powerful approach to multiple testing. J R Statist Soc B. 1995;57:289–300.

29.

Hatt M, Cheze-Le Rest C, Aboagye EO, Kenny LM, Rosso L, Turkheimer FE, et al. Reproducibility of 18F-FDG and 3’-deoxy-3’-18F-fluorothymidine PET tumor volume measurements. J Nucl Med. 2010;51:1368–76.CrossRefPubMed

30.

Vesselle H, Schmidt RA, Pugsley JM, Li M, Kohlmyer SG, Vallires E, et al. Lung cancer proliferation correlates with [F-18]fluorodeoxyglucose uptake by positron emission tomography. Clin Cancer Res. 2000;6:3837–44.PubMed

31.

Kunkel M, Reichert TE, Benz P, Lehr H-A, Jeong J-H, Wieand S, et al. Overexpression of Glut-1 and increased glucose metabolism in tumors are associated with a poor prognosis in patients with oral squamous cell carcinoma. Cancer. 2003;97:1015–24.CrossRefPubMed

32.

Tixier F, Groves AM, Goh V, Hatt M, Ingrand P, Le Rest CC, et al. Correlation of intra-tumor 18F-FDG uptake heterogeneity indices with perfusion CT derived parameters in colorectal cancer. PLoS One. 2014;9:e99567.CrossRefPubMedPubMedCentral

33.

Rajendran JG, Wilson DC, Conrad EU, Peterson LM, Bruckner JD, Rasey JS, et al. [(18)F]FMISO and [(18)F]FDG PET imaging in soft tissue sarcomas: correlation of hypoxia, metabolism and VEGF expression. Eur J Nucl Med Mol Imaging. 2003;30:695–704.CrossRefPubMed

34.

Ikehara M, Saito H, Yamada K, Oshita F, Noda K, Nakayama H, et al. Prognosis of small adenocarcinoma of the lung based on thin-section computed tomography and pathological preparations. J Comput Assist Tomogr. 2008;32:426–31.CrossRefPubMed

35.

Ganeshan B, Panayiotou E, Burnand K, Dizdarevic S, Miles K. Tumour heterogeneity in non-small cell lung carcinoma assessed by CT texture analysis: a potential marker of survival. Eur Radiol. 2012;22:796–802.CrossRefPubMed

36.

Yan J, Chu-Shern JL, Loi HY, Khor LK, Sinha AK, Quek ST, et al. Impact of image reconstruction settings on texture features in 18F-FDG PET. J Nucl Med. 2015;56:1667–73.CrossRefPubMed

37.

Yip S, McCall K, Aristophanous M, Chen AB, Aerts HJ, Berbeco R. Comparison of texture features derived from static and respiratory-gated PET images in non-small cell lung cancer. PLoS One. 2014;9:e115510.CrossRefPubMedPubMedCentral

38.

Parmar C, Grossmann P, Bussink J, Lambin P, Aerts HJ. Machine learning methods for quantitative radiomic biomarkers. Sci Rep. 2015;5:13087.CrossRefPubMedPubMedCentral

Titel: Development of a nomogram combining clinical staging with 18F-FDG PET/CT image features in non-small-cell lung cancer stage I–III
verfasst von: Marie-Charlotte Desseroit
Dimitris Visvikis
Florent Tixier
Mohamed Majdoub
Rémy Perdrisot
Rémy Guillevin
Catherine Cheze Le Rest
Mathieu Hatt
Publikationsdatum: 20.02.2016
Verlag: Springer Berlin Heidelberg
Erschienen in: European Journal of Nuclear Medicine and Molecular Imaging / Ausgabe 8/2016
Print ISSN: 1619-7070
Elektronische ISSN: 1619-7089
DOI: https://doi.org/10.1007/s00259-016-3325-5

Live-Webinar: Aktuelle Leitlinien bei Herz-Kreislauf-Erkrankungen

Springer Medizin

Development of a nomogram combining clinical staging with ¹⁸F-FDG PET/CT image features in non-small-cell lung cancer stage I–III

Abstract

Purpose

Methods

Results

Conclusion

Live-Webinar: Aktuelle Leitlinien bei Herz-Kreislauf-Erkrankungen

Springer Medizin

Abstract

Purpose

Methods

Results

Conclusion

Bitte loggen Sie sich ein, um Zugang zu diesem Inhalt zu erhalten

Weitere Artikel der Ausgabe 8/2016

Clinical use of quantitative cardiac perfusion PET: rationale, modalities and possible indications. Position paper of the Cardiovascular Committee of the European Association of Nuclear Medicine (EANM)

Selective internal radiation therapy in patients with progressive neuroendocrine liver metastases

The 2015 Revised American Thyroid Association guidelines for the management of medullary thyroid carcinoma: the “evidence-based” refusal to endorse them by EANM due to the “not evidence-based” marginalization of the role of Nuclear Medicine

Molecular imaging using PSMA PET/CT versus multiparametric MRI for initial staging of prostate cancer: comparing apples with oranges?

The dark side of the moon of coronary vasodilation

Riemer H.J.A.Slart, René A.Tio, Philip H.Elsinga, Markus Schwaiger (Eds): Autonomic Innervation of the Heart: Role of Molecular Imaging